Infectious disease
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.
Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.
The Biden administration announced plans for a new biopreparedness initiative that is part of the ongoing Building Back Better plan.
Concerns about Mu and Lambda are growing, but data suggests that Delta is still the biggest problem. The U.S. is also struggling with infections this year. Here’s the latest news.
Celsion announced results from its PLACCINE DNA vaccine platform that showed it produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2.
The Mu variation is the fifth strain to be designated as a “variant of interest” by the World Health Organization.
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
Pfizer dosed its first patients in a Phase III trial assessing a single dose of its investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and above.
A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.
PRESS RELEASES